What should you know about pleomorphic LCIS pathology outlines?

Look for the specimen type, the location sampled, and the description of the cells. The report may distinguish pleomorphic LCIS from classic LCIS and may record whether necrosis, calcification, or another lesion is present. It may also state whether the finding reaches an edge of the sampled tissue, although an edge on a biopsy does not by itself show how much tissue remains in the breast.

Pathology terms describe the sample under a microscope; they do not replace the breast examination or imaging review. A radiology-pathology discussion may be needed when the tissue result does not fully explain the imaging appearance.

Request a copy of the complete report and ask the breast team to translate each phrase into a practical plan. They may recommend review by another pathologist, more tissue sampling, surgical excision, or structured surveillance. The choice considers the imaging target, amount of pleomorphic LCIS, family history, previous procedures, and your comfort with each option.

Risk-reducing endocrine therapy may be considered for selected patients. If tissue has been removed, follow-up after cancer treatment can provide a framework for keeping imaging and clinical reviews organised, with the schedule tailored to your situation.

Tell the breast team about a new or enlarging lump, nipple inversion, spontaneous discharge, skin dimpling, or a change that persists. These signs can have several causes and do not prove that LCIS has become invasive disease, but they should be examined. After biopsy or surgery, seek prompt advice for fever, spreading redness, pus, uncontrolled bleeding, or sudden severe pain.

Which line confirms pleomorphic LCIS? Is the result concordant with my imaging? Was the sample sufficient? Is excision recommended? How will you monitor the other breast and the sampled area? Should I consider risk-reducing endocrine therapy?